[应对抗生素耐药性的新抗生素]。

Q4 Medicine Revue Du Praticien Pub Date : 2023-06-01

Pauline Huriez, Benoît Pilmis

{"title":"[应对抗生素耐药性的新抗生素]。","authors":"Pauline Huriez, Benoît Pilmis","doi":"","DOIUrl":null,"url":null,"abstract":"NEW ANTIBIOTICS TO DEAL WITH ANTIBIOTIC RESISTANCE. The current increase in antibiotic resistance exposes to the risk of therapeutic impasse. To deal with this public health problem, developing new antibiotics that are effective (directly or in combination with older drugs) against these multi-resistant bacteria seems important. Over the last 10 years, new drugs (beta-lactams, beta-lactamase inhibitors, cyclin and carbapenems) have been developed against Gram-negative bacteria. A new oxazolidinone, two glycopeptides and a quinolone have been developed against Gram-positive bacteria. Their use must absolutely be controlled to avoid resistance mechanisms emergence.","PeriodicalId":21248,"journal":{"name":"Revue Du Praticien","volume":"73 6","pages":"587-592"},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[New antibiotics to deal with antibiotic resistance].\",\"authors\":\"Pauline Huriez, Benoît Pilmis\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"NEW ANTIBIOTICS TO DEAL WITH ANTIBIOTIC RESISTANCE. The current increase in antibiotic resistance exposes to the risk of therapeutic impasse. To deal with this public health problem, developing new antibiotics that are effective (directly or in combination with older drugs) against these multi-resistant bacteria seems important. Over the last 10 years, new drugs (beta-lactams, beta-lactamase inhibitors, cyclin and carbapenems) have been developed against Gram-negative bacteria. A new oxazolidinone, two glycopeptides and a quinolone have been developed against Gram-positive bacteria. Their use must absolutely be controlled to avoid resistance mechanisms emergence.\",\"PeriodicalId\":21248,\"journal\":{\"name\":\"Revue Du Praticien\",\"volume\":\"73 6\",\"pages\":\"587-592\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue Du Praticien\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Du Praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

应对抗生素耐药性的新抗生素。目前抗生素耐药性的增加面临着治疗僵局的风险。为了解决这一公共卫生问题，开发对这些多重耐药细菌有效(直接或与旧药物联合)的新抗生素似乎很重要。在过去的10年里，针对革兰氏阴性菌的新药(β -内酰胺类药物、β -内酰胺酶抑制剂、细胞周期素和碳青霉烯类药物)已经被开发出来。研制了一种新的抗革兰氏阳性菌的恶唑烷酮、两种糖肽和一种喹诺酮。它们的使用必须绝对控制，以避免耐药性机制的出现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[New antibiotics to deal with antibiotic resistance].

NEW ANTIBIOTICS TO DEAL WITH ANTIBIOTIC RESISTANCE. The current increase in antibiotic resistance exposes to the risk of therapeutic impasse. To deal with this public health problem, developing new antibiotics that are effective (directly or in combination with older drugs) against these multi-resistant bacteria seems important. Over the last 10 years, new drugs (beta-lactams, beta-lactamase inhibitors, cyclin and carbapenems) have been developed against Gram-negative bacteria. A new oxazolidinone, two glycopeptides and a quinolone have been developed against Gram-positive bacteria. Their use must absolutely be controlled to avoid resistance mechanisms emergence.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊